CIK 0001000694
- Large accelerated filer
NOVAVAX INC
Sign in to watch- Ticker
- NVAX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 222816046
- Phone
- +1 240-268-2000
- Business address
- 21 FIRSTFIELD RD, GAITHERSBURG, MD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-15 | Glenn Gregory M President, R&D | Sale | −1,282 | $200.14 | $257K | 2,911 |
| 2021-03-15 | Glenn Gregory M President, R&D | Sale | −100 | $201.47 | $20K | 2,811 |
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion | +4,819 | $217.46 | $1.0M | 7,630 |
| 2021-03-15 | Glenn Gregory M President, R&D | Returned to the company | −132 | $217.46 | $29K | 7,498 |
| 2021-03-15 | Glenn Gregory M President, R&D | Shares withheld for taxes | −2,264 | $217.46 | $492K | 5,234 |
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion · Stock Option (Right to Buy) | −619 | 1,861 | ||
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion · Stock Option (Right to Buy) | −868 | 6,605 | ||
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion · Stock Option (Right to Buy) | −1,101 | 16,322 | ||
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion · Stock Option (Right to Buy) | −3,124 | 68,752 | ||
| 2021-03-15 | Glenn Gregory M President, R&D | Exercise or conversion · Stock Appreciation Right | −4,819 | 56,462 | ||
| 2021-03-09 | Trizzino John EVP, Chief Commercial Officer | Sale | −190 | $168.09 | $32K | 287 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Exercise or conversion | +417 | $27.60 | $12K | 704 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Exercise or conversion | +521 | $46.00 | $24K | 1,225 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Exercise or conversion | +2,083 | $5.95 | $12K | 3,308 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −72 | $150.31 | $11K | 3,236 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −150 | $152.39 | $23K | 3,086 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −312 | $153.24 | $48K | 2,774 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −185 | $154.00 | $28K | 2,589 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −135 | $155.64 | $21K | 2,454 |
| 2021-03-05 | Trizzino John EVP, Chief Commercial Officer | Sale | −160 | $157.08 | $25K | 2,294 |
Page 66 of 87 · 1,734 trades